Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 30, 2025 -- Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA), according to a study published online March 29 in the Annals of the Rheumatic Diseases.
Rachel A. Charlton, Ph.D., from the University of Bath in the United Kingdom, and colleagues compared time to diagnosis among patients with PsA and patients with RA. The analysis included 2,120 patients with PsA matched to patients with RA.
The researchers found that symptom duration before referral was longer in patients with PsA than in those with RA. Patients with PsA had a longer time from general practitioner presentation to diagnosis (mean, 112 versus 89 days; hazard ratio [HR], 0.87), including a delay in diagnosis once referrals were received in secondary care (HR, 0.86). For those with polyarticular disease, fewer disease-modifying antirheumatic drugs were prescribed at baseline for PsA versus RA (54.0 and 69.0 percent, respectively). At baseline, patients with RA had a higher Disease Activity Score in 28 joints, but by three months, the average score was higher in patients with PsA.
"These findings highlight the need for education both of patients and the clinical team, to support earlier diagnosis and treatment, thus improving longer-term outcomes," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Central Adiposity Measures Associated With Psoriasis Risk
TUESDAY, June 3, 2025 -- Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a research letter published...
Psoriasis Tied to Increased Risk for Sleep Disorders
MONDAY, June 2, 2025 -- Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online...
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
WEDNESDAY, May 21, 2025 -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.